Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis

Bibliography

• Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001;15:16-7
   PubMed Web of Science ®Google Scholar
• Lebwohl M. Psoriasis. Lancet 2003;361:1197-204
   PubMed Web of Science ®Google Scholar
• Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352:1899-912
   PubMed Web of Science ®Google Scholar
• Fortune DG, Richards HL, Griffiths CE. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin 2005;23:681-94
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7
   PubMed Web of Science ®Google Scholar
• Austin LM, Ozawa M, Kikuchi T, The majority of epidermal T cells in psoriasis vulgaris lesions can produce type I cytokines, IFN-gamma, IL-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type I differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999;113:752-9
   PubMed Web of Science ®Google Scholar
• Bos JD, Hulsebosch HJ, Krieg SR, Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983;275:181-9
   PubMed Web of Science ®Google Scholar
• Steinman L. A rush to judgment on Th17. J Exp Med 2008;205:1517-22
   PubMed Web of Science ®Google Scholar
• McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006;27:17-23
   PubMed Web of Science ®Google Scholar
• Vanden Eijnden S, Goriely S, De Wit D, IL-23 up-regulates IL-10 and induces IL-17 synthesis by polyclonally activated naïve T cells in human. Eur J Immunol 2005;35:469-75
   PubMed Web of Science ®Google Scholar
• Caproni M, Antiga E, Melani L, Serum levels of IL-17 and IL-22 are reduced by etanercept, but not acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 2009;29:210-14
   PubMed Web of Science ®Google Scholar
• Liu H and Rohowsky-Kochan C. Regulation of IL-17 in human CCR6+ effector memory T cells. J Immunol 2008;180:7948-57
   PubMed Web of Science ®Google Scholar
• Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8:942-9
   PubMed Web of Science ®Google Scholar
• Hehlgans T, Pfeffer K. The intriguing biology of tumor necrosis factor/tumor necrosis factor receptor superfamily: players, rules, and the games. Immunology 2005;115:1-20
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Chamian F, Masud S, TNF inhibition rapidly down-regulates multiple pro-inflammatory pathways in psoriasis plaques. J Immunol 2005;175:2721-9
   PubMed Web of Science ®Google Scholar
• Zaba LC, Cardinale I, Gilleaudeau P, Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204:3183-94
   PubMed Web of Science ®Google Scholar
• Yawalkar N, Karlen S, Hunger R, Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 1998;111:1053-7
   PubMed Web of Science ®Google Scholar
• Piskin G, Sylva-Steenland RMR, Bos JD, Teunissen MBM. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriatic lesions: enhanced expression in psoriatic skin. J Immunol 2006;176:1908-15
   PubMed Web of Science ®Google Scholar
• Cargill M, Schrodi SJ, Chang M, A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007;80:273-90
   PubMed Web of Science ®Google Scholar
• Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007;57:1059-68
   PubMed Web of Science ®Google Scholar
• Kimball AB, Gordon KB, Langley RG, Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis. Arch Dermatol 2008;144:200-7
   PubMed Web of Science ®Google Scholar
• Krueger GG, Langely RG, Leonardi C, A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, Efficacy and Safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Strober BF, van de Kerkhof P, Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-28
   PubMed Web of Science ®Google Scholar
• Kasper LH, Everitt D, Leist T, Safety, pharmacokinetic, and biological response profile of an IL-12p40 antagonist in MS: a phase I clinical trial. Proc Congress Eur Committee Treat Res Mult Scler 2004;107-15
   Google Scholar
• Kauffman CL, Aria N, Toichi E, A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004;123:1037-44
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Cooper KD, McCormick TS, A phase 1, double blind, placebo-controlled study evaluating single subcutaneous administration of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin 2007;23:1081-92
   PubMed Web of Science ®Google Scholar
• O'Neill JL, Kalb RE. Ustekinumab in the therapy of chronic plaque psoriasis. Biol Targets Ther 2009;3:159-68
   PubMedGoogle Scholar
• Toichi E, McCormick TS, Kaufmann CL, Quantitation of cutaneous cytokine mRNA levels following anti-IL-12 psoriasis therapy: identification of a psoriasis subset. J Invest Dermatol 2003;121:1249
   Google Scholar
• de Jong R, Altare F, Haagen IA, Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 1998;280(5368):1435-8
   PubMed Web of Science ®Google Scholar
• Doffinger R, Dupuis S, Picard C, Inherited disorders of IL-12 and IFN-gamma-mediated immunity: a molecular genetics update. Mol Immunol 2002;38(12-13):903-9
   PubMed Web of Science ®Google Scholar
• Niemann AL, Shin DB, Wang X, Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-35
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Neiman AL, Shin DB, Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41
   PubMed Web of Science ®Google Scholar
• Korth-Bradley JM, Rubin AS, Hanna RK, The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000;34:161-4
   PubMed Web of Science ®Google Scholar
• Enbrel (etanercept) [package insert]. Thousand Oaks, Calif: Amgen Inc and Wyeth-Ayerst Pharmaceuticals; 2006
   Google Scholar
• Van de Kerkhof PC, Segaert S, Lahfa M, Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008;159:1177-85
   PubMed Web of Science ®Google Scholar
• Ortonne J-P, Griffiths C, Daudén E, Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54weeks: the CRYSTEL study. Exp Rev Dermatol 2008;3:657-65
   Google Scholar
• Tyring S, Gottlieb A, Papp K, Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet 2006;367:29-35
   PubMed Web of Science ®Google Scholar
• de Vlam K, Lories RJU. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology 2006;45:321-4
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Lowe N, A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-32
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT, Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-12
   PubMed Web of Science ®Google Scholar
• Mease P, Kivitz A, Burch F, Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel): results of a phase 3 multicenter clinical trial. Arthritis Rheum 2001;44:S90
   Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Langley RG, Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008;358:241-51
   PubMed Web of Science ®Google Scholar
• Tyring S, Gordon KB, Poulin Y, Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719-72
   PubMed Web of Science ®Google Scholar
• Sterry W, Ortonne JP, Kirkham B, Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomized double-blind multicentre trial. BMJ 2010;340:c147
   PubMed Web of Science ®Google Scholar
• Moreland LW, Weinblatt ME, Keystone EC, Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006;33:854-61
   PubMed Web of Science ®Google Scholar
• Driessen RJB, Bowzeman JB, van de Kerkhof PCM, de Jong EMGJ. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 2009;160:670-5
   PubMed Web of Science ®Google Scholar
• Moreland LW, Baumgartner SW, Schiff MH, Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)–Fc fusion protein. N Engl J Med 1997;337:141-7
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-86
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9
   PubMed Web of Science ®Google Scholar
• Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005;25:1181-92
   PubMed Web of Science ®Google Scholar
• Sukal SA, Nadiminti L, Granstein RD. Etanercept and demyelinating disease in a patient with psoriasis. J Am Acad Dermatol 2006;54:160-4
   PubMed Web of Science ®Google Scholar
• Lebwohl M. New developments in the treatment of psoriasis. Arch Dermatol 2002;138:686-8
   PubMed Web of Science ®Google Scholar
• Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502
   PubMed Web of Science ®Google Scholar
• Baecklund E, Ekbom A, Sparen P, Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180-81
   PubMed Web of Science ®Google Scholar
• Keystone EC. Safety of biologic therapies-an update. J Rheumatol Suppl 2005;74:8-12
   PubMedGoogle Scholar
• Hannuksela-Svahn A, Pukkala E, Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000;114:587-90
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Strober BE, van de Kerkhof P, Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-28
   PubMed Web of Science ®Google Scholar
• Sokka T. Rheumatoid arthritis databases. Rheum Dis Clin North Am 2004;30:769-81
   PubMed Web of Science ®Google Scholar
• Richards HL, Fortune DG, Griffiths CE. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol 2006;20:370-9
   PubMed Web of Science ®Google Scholar
• Zaghloul SS, Goodfield MJD. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004;140:408-14
   PubMed Web of Science ®Google Scholar
• Stern RS, Nijsten T, Feldman SR, Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermaol Symp Proc 2004;9:136-9
   PubMed Web of Science ®Google Scholar